- Home
- MNOV vs ALXO Comparison
MNOV vs ALXO Comparison
Compare MNOV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ALXO |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 79.7M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNOV | ALXO |
|---|---|---|
| Price | $1.27 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $7.00 | $3.30 |
| AVG Volume (30 Days) | 79.4K | ★ 173.8K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,917.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $0.40 |
| 52 Week High | $2.20 | $2.27 |
Technical Indicators
Market Signals| Indicator | MNOV | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 32.65 | 42.54 |
| Support Level | $1.48 | $1.37 |
| Resistance Level | $1.51 | $1.53 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 10.00 | 12.12 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.